← All trials
NCT02423863
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2015
- Primary completion
- Dec 1, 2018
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Oncovir, Inc.Lead sponsor
- University of PittsburghOverall official - principal investigator
- Bay Hematology OncologyOverall official - principal investigator
- Emory UniversityOverall official - principal investigator
- Emory UniversityCollaborator
- University of PittsburghCollaborator
- National Cancer Institute (NCI)Collaborator
- Bay Hematology OncologyCollaborator
- Medical University of South CarolinaCollaborator
- National Institutes of Health (NIH)Collaborator
- University of MissouriCollaborator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.